Multidrug resistance: Physiological principles and nanomedical solutions

Advanced Drug Delivery Reviews

Volumn 65, Issue 13-14, 2013, Pages 1852-1865

  Kunjachan, Sijumon ^a   Rychlik, Błazej ^b   Storm, Gert ^c,d   Kiessling, Fabian ^a   Lammers, Twan ^a,c,d  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF LODZ   (Poland)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

ABC transporters; Drug efflux pumps; Drug targeting; MDR; MRP; Multidrug resistance; Nanomedicine; Pgp; Pluronics; SiRNA

Indexed keywords

CELL MEMBRANES; GLYCOPROTEINS; MEDICAL NANOTECHNOLOGY; MOLECULAR WEIGHT; PHYSIOLOGY; PROTEINS; TARGETED DRUG DELIVERY;

ABC TRANSPORTER; DRUG EFFLUX PUMPS; DRUG-TARGETING; MULTIDRUG RESISTANCE; PLURONICS; SIRNA;

CONTROLLED DRUG DELIVERY;

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; COLCHICINE; CYCLOSPORIN A; DACTINOMYCIN; DEMECOLCINE; DOXORUBICIN; ELACRIDAR; EPOTHILONE DERIVATIVE; MACROGOL; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NANOCARRIER; PACLITAXEL; POLOXAMER; POLYCAPROLACTONE; POLYMER; SMALL INTERFERING RNA; TAMOXIFEN; TARIQUIDAR; TAXANE DERIVATIVE; TOPOTECAN; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL MEMBRANE; COLON ADENOCARCINOMA; COLON CARCINOMA; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; GLIOMA; HUMAN; IC 50; MELANOMA; MICELLE; MONOTHERAPY; MULTIDRUG RESISTANCE; NANOMEDICINE; NONHUMAN; OVARY CARCINOMA; PARTICLE SIZE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SQUAMOUS CELL CARCINOMA; UTERUS SARCOMA;

ABC TRANSPORTERS; DRUG EFFLUX PUMPS; DRUG TARGETING; MDR; MRP; MULTIDRUG RESISTANCE; NANOMEDICINE; PGP; PLURONICS; SIRNA;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; HUMANS; MOLECULAR TARGETED THERAPY; NANOMEDICINE; NANOSTRUCTURES; ORGAN SPECIFICITY; PHARMACEUTICAL PREPARATIONS; PROTEIN TRANSPORT; SUBSTRATE SPECIFICITY;

EID: 84888206276     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.09.018     Document Type: Review

References (109)

1. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011, 71:3-10.
2. Ling V., Thompson L.H. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J. Cell. Physiol. 1974, 83:103-116.
3. See Y.P., Carlsen S.A., Till J.E., Ling V. Increased drug permeability in Chinese hamster ovary cells in the presence of cyanide. Biochim. Biophys. Acta 1974, 373:242-252.
4. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 1976, 455:152-162.
5. Chen Y.N., Mickley L.A., Schwartz A.M., Acton E.M., Hwang J.L., Fojo A.T. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J. Biol. Chem. 1990, 265:10073-10080.
6. Cole S.P., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M., Deeley R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258:1650-1654.
7. Hyde S.C., Emsley P., Hartshorn M.J., Mimmack M.M., Gileadi U., Pearce S.R., Gallagher M.P., Gill D.R., Hubbard R.E., Higgins C.F. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 1990, 346:362-365.
8. Dean M. The Human ATP-Binding Cassette (ABC) Transporter Superfamily 2002.
9. Chen C.J., Chin J.E., Ueda K., Clark D.P., Pastan I., Gottesman M.M., Roninson I.B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47:381-389.
10. Bakos E., Hegedus T., Hollo Z., Welker E., Tusnady G.E., Zaman G.J., Flens M.J., Varadi A., Sarkadi B. Membrane topology and glycosylation of the human multidrug resistance-associated protein. J. Biol. Chem. 1996, 271:12322-12326.
11. Ito K.i., Weig K.E., Deeley R.G., Cole S.P.C. Mutation of proline residues in the NH(2)-terminal region of the multidrug resistance protein, MRP1 (ABCC1): effects on protein expression, membrane localization, and transport function. Biochim. Biophys. Acta 2003, 1615:103-114.
12. Fernandez S.B.M., Hollo Z., Kern A., Bakos E., Fischer P.A., Borst P., Evers R. Role of the N-terminal transmembrane region of the multidrug resistance protein MRP2 in routing to the apical membrane in MDCKII cells. J. Biol. Chem. 2002, 277:31048-31055.
13. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., Ross D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:15665-15670.
14. McDevitt C.A., Collins R.F., Conway M., Modok S., Storm J., Kerr I.D., Ford R.C., Callaghan R. Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2. Structure 2006, 14:1623-1632.
15. Syberg F., Suveyzdis Y., Kotting C., Gerwert K., Hofmann E. Time-resolved Fourier transform infrared spectroscopy of the nucleotide-binding domain from the ATP-binding Cassette transporter MsbA: ATP hydrolysis is the rate-limiting step in the catalytic cycle. J. Biol. Chem. 2012, 287:23923-23931.
16. Hamada H., Tsuruo T. Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988, 48:4926-4932.
17. Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A., Pijnenborg A.C., Schinkel A.H., van De Vijver M.J., Scheper R.J., Schellens J.H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001, 61:3458-3464.
18. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:7735-7738.
19. Evers R., Zaman G.J., van Deemter L., Jansen H., Calafat J., Oomen L.C., Oude Elferink R.P., Borst P., Schinkel A.H. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J. Clin. Invest. 1996, 97(5):1211-1218.
20. Storch C.H., Ehehalt R., Haefeli W.E., Weiss J. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J. Pharmacol. Exp. Ther. 2007, 323:257-264.
21. Herzog M., Storch C.H., Gut P., Kotlyar D., Fullekrug J., Ehehalt R., Haefeli W.E., Weiss J. Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity. Naunyn Schmiedebergs Arch. Pharmacol. 2011, 383:1-11.
22. Fenyvesi F., Fenyvesi E., Szente L., Goda K., Bacso Z., Bacskay I., Varadi J., Kiss T., Molnar E., Janaky T., Szabo G., Vecsernyes M. P-glycoprotein inhibition by membrane cholesterol modulation. Eur. J. Pharm. Sci. 2008, 34:236-242.
23. Meszaros P., Klappe K., Hummel I., Hoekstra D., Kok J.W. Function of MRP1/ABCC1 is not dependent on cholesterol or cholesterol-stabilized lipid rafts. Biochem. J. 2011, 437:483-491.
24. Sugawara I., Akiyama S., Scheper R.J., Itoyama S. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Lett. 1997, 112:23-31.
25. Aronica E., Gorter J.A., Redeker S., van Vliet E.A., Ramkema M., Scheffer G.L., Scheper R.J., van der Valk P., Leenstra S., Baayen J.C., Spliet W.G.M., Troost D. Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 2005, 46:849-857.
26. Uematsu T., Yamaoka M., Doto R., Tanaka H., Matsuura T., Furusawa K. Expression of ATP-binding cassette transporter in human salivary ducts. Arch. Oral Biol. 2003, 48:87-90.
27. Pavelic Z.P., Reising J., Pavelic L., Kelley D.J., Stambrook P.J., Gluckman J.L. Detection of P-glycoprotein with four monoclonal antibodies in normal and tumor tissues. Arch. Otolaryngol. Head Neck Surg. 1993, 119:753-757.
28. Fetsch P.A., Abati A., Litman T., Morisaki K., Honjo Y., Mittal K., Bates S.E. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett. 2006, 235:84-92.
29. Scoazec J.Y., Bringuier A.F., Medina J.F., Martínez-Ansó E., Veissiere D., Feldmann G., Housset C. The plasma membrane polarity of human biliary epithelial cells: in situ immunohistochemical analysis and functional implications. J. Hepatol. 1997, 26:543-553.
30. Bart J., Hollema H., Groen H.J.M., de Vries E.G.E., Hendrikse N.H., Sleijfer D.T., Wegman T.D., Vaalburg W., van der Graaf W.T.A. The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur. J. Cancer 2004, 40:2064-2070.
31. Robillard K.R., Hoque T., Bendayan R. Expression of ATP-binding cassette membrane transporters in rodent and human sertoli cells: relevance to the permeability of antiretroviral therapy at the blood-testis barrier. J. Pharmacol. Exp. Ther. 2012, 340:96-108.
32. Atkinson D.E., Sibley C.P., Fairbairn L.J., Greenwood S.L. MDR1 P-gp expression and activity in intact human placental tissue; upregulation by retroviral transduction. Placenta 2006, 27:707-714.
33. St-Pierre M.V., Serrano M.A., Macias R.I., Dubs U., Hoechli M., Lauper U., Meier P.J., Marin J.J. Expression of members of the multidrug resistance protein family in human term placenta. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 279:R1495-R1503.
34. Kock K., Grube M., Jedlitschky G., Oevermann L., Siegmund W., Ritter C.A., Kroemer H.K. Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy. Clin. Pharmacokinet. 2007, 46:449-470.
35. Pulaski L., Jedlitschky G., Leier I., Buchholz U., Keppler D. Identification of the multidrug-resistance protein (MRP) as the glutathione-S-conjugate export pump of erythrocytes. Eur. J. Biochem. 1996, 241:644-648.
36. Zhou S., Zong Y., Ney P.A., Nair G., Stewart C.F., Sorrentino B.P. Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels. Blood 2005, 105:2571-2576.
37. Saison C., Helias V., Ballif B.A., Peyrard T., Puy H., Miyazaki T., Perrot S.Ã., Vayssier-Taussat M., Waldner M., Le Pennec P.Y., Cartron J.P., Arnaud L. Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior. Nat. Genet. 2012, 44:174-177.
38. Sjolinder M., Tornhamre S., Claesson H.E., Hydman J., Lindgren J. Characterization of a leukotriene C4 export mechanism in human platelets: possible involvement of multidrug resistance-associated protein 1. J. Lipid Res. 1999, 40:439-446.
39. Zhou S., Schuetz J.D., Bunting K.D., Colapietro A.M., Sampath J., Morris J.J., Lagutina I., Grosveld G.C., Osawa M., Nakauchi H., Sorrentino B.P. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 2001, 7:1028-1034.
40. Spiegl-Kreinecker S., Buchroithner J., Elbling L., Steiner E., Wurm G., Bodenteich A., Fischer J., Micksche M., Berger W. Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes. J. Neurooncol. 2002, 57:27-36.
41. Bellamy W.T., Dalton W.S., Kailey J.M., Gleason M.C., McCloskey T.M., Dorr R.T., Alberts D.S. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res. 1988, 48:6365-6370.
42. Zaman G.J., Flens M.J., van Leusden M.R., de Haas M., Mulder H.S., Lankelma J., Pinedo H.M., Scheper R.J., Baas F., Broxterman H.J. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:8822-8826.
43. Horio M., Gottesman M.M., Pastan I. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:3580-3584.
44. Slovak M.L., Hoeltge G.A., Dalton W.S., Trent J.M. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res. 1988, 48:2793-2797.
45. Renes J., de Vries E.G., Nienhuis E.F., Jansen P.L., MÃ1/4ller M. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br. J. Pharmacol. 1999, 126:681-688.
46. Brangi M., Litman T., Ciotti M., Nishiyama K., Kohlhagen G., Takimoto C., Robey R., Pommier Y., Fojo T., Bates S.E. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 1999, 59:5938-5946.
47. Sugiyama Y., Kato Y., Chu X. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother. Pharmacol. 1998, 42:S44-S49. (Suppl.).
48. Burger H., van Tol H., Boersma A.W.M., Brok M.l., Wiemer E.A.C., Stoter G., Nooter K. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004, 104:2940-2942.
49. Thomas J., Wang L., Clark R.E., Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004, 104:3739-3745.
50. Zeng H., Chen Z.S., Belinsky M.G., Rea P.A., Kruh G.D. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001, 61:7225-7232.
51. Volk E.L., Rohde K., Rhee M., McGuire J.J., Doyle L.A., Ross D.D., Schneider E. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res. 2000, 60:3514-3521.
52. Chen Z.S., Robey R.W., Belinsky M.G., Shchaveleva I., Ren X.Q., Sugimoto Y., Ross D.D., Bates S.E., Kruh G.D. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003, 63:4048-4054.
53. Wils P., Phung-Ba V., Warnery A., Lechardeur D., Raeissi S., Hidalgo I.J., Scherman D. Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem. Pharmacol. 1994, 48:1528-1530.
54. Shen H., Lee F.Y., Gan J. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J. Pharmacol. Exp. Ther. 2011, 337:423-432.
55. Barnouin K., Leier I., Jedlitschky G., Pourtier-Manzanedo A., Konig J., Lehmann W.D., Keppler D. Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione. Br. J. Cancer 1998, 77:201-209.
56. Abulrob A.G., Gumbleton M. Transport of phosphatidylcholine in MDR3-negative epithelial cell lines via drug-induced MDR1 P-glycoprotein. Biochem. Biophys. Res. Commun. 1999, 262:121-126.
57. Neyfakh A.A., Serpinskaya A.S., Chervonsky A.V., Apasov S.G., Kazarov A.R. Multidrug-resistance phenotype of a subpopulation of T-lymphocytes without drug selection. Exp. Cell Res. 1989, 185:496-505.
58. Eytan G.D., Regev R., Oren G., Hurwitz C.D., Assaraf Y.G. Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug-resistant cells is determined by their passive transmembrane movement rate. Eur. J. Biochem. 1997, 248:104-112.
59. Homolya L., Hollo Z., Germann U.A., Pastan I., Gottesman M.M., Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J. Biol. Chem. 1993, 268:21493-21496.
60. Hollo Z., Homolya L., Hegedus T., Sarkadi B. Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells. FEBS Lett. 1996, 383:99-104.
61. Draper M.P., Martell R.L., Levy S.B. Active efflux of the free acid form of the fluorescent dye 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein in multidrug-resistance-protein-overexpressing murine and human leukemia cells. Eur. J. Biochem. 1997, 243:219-224.
62. Keppler D., Cui Y., Konig J., Leier I., Nies A. Export pumps for anionic conjugates encoded by MRP genes. Adv. Enzyme Regul. 1999, 39:237-246.
63. Dekkers D.W., Comfurius P., Schroit A.J., Bevers E.M., Zwaal R.F. Transbilayer movement of NBD-labeled phospholipids in red blood cell membranes: outward-directed transport by the multidrug resistance protein 1 (MRP1). Biochemistry 1998, 37:14833-14837.
64. Raggers R.J., van Helvoort A., Evers R., van Meer G. The human multidrug resistance protein MRP1 translocates sphingolipid analogs across the plasma membrane. J. Cell Sci. 1999, 112(Pt 3):415-422.
65. Scharenberg C.W., Harkey M.A., Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002, 99:507-512.
66. Sharom F.J. The P-glycoprotein multidrug transporter. Essays Biochem. 2011, 50:161-178.
67. Rao U.S., Fine R.L., Scarborough G.A. Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem. Pharmacol. 1994, 48:287-292.
68. Drach J., Gsur A., Hamilton G., Zhao S., Angerler J., Fiegl M., Zojer N., Raderer M., Haberl I., Andreeff M., Huber H. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 1996, 88:1747-1754.
69. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A., van der Valk M.A., Robanus-Maandag E.C.,Riele H.P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77:491-502.
70. Schinkel A.H., Mayer U., Wagenaar E., Mol C.A., van Deemter L., Smit J.J., van der Valk M.A., Voordouw A.C., Spits H., van Tellingen O., Zijlmans J.M., Fibbe W.E., Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:4028-4033.
71. Jedlitschky G., Leier I., Buchholz U., Center M., Keppler D. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res. 1994, 54:4833-4836.
72. Jedlitschky G., Leier I., Buchholz U., Barnouin K., Kurz G., Keppler D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 1996, 56:988-994.
73. Jedlitschky G., Leier I., Buchholz U., Hummel-Eisenbeiss J., Burchell B., Keppler D. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem. J. 1997, 327(Pt 1):305-310.
74. Leier I., Jedlitschky G., Buchholz U., Center M., Cole S.P., Deeley R.G., Keppler D. ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Biochem. J. 1996, 314(Pt 2):433-437.
75. Balcerczyk A., Rychlik B.Å., Kruszewski M., Burchell B., Bartosz G. MRP1-transfected cells do not show increased resistance against oxidative stress. Free Radic. Res. 2003, 37:189-195.
76. Leier I., Jedlitschky G., Buchholz U., Cole S.P., Deeley R.G., Keppler D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem. 1994, 269:27807-27810.
77. Wijnholds J., Evers R., van Leusden M.R., Mol C.A., Zaman G.J., Mayer U., Beijnen J.H., van der Valk M., Krimpenfort P., Borst P. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat. Med. 1997, 3:1275-1279.
78. Jonker J.W., Buitelaar M., Wagenaar E., Van Der Valk M.A., Scheffer G.L., Scheper R.J., Plosch T., Kuipers F., Elferink R.P.J.O., Rosing H., Beijnen J.H., Schinkel A.H. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:15649-15654.
79. Nakayama A., Matsuo H., Takada T., Ichida K., Nakamura T., Ikebuchi Y., Ito K., Hosoya T., Kanai Y., Suzuki H., Shinomiya N. ABCG2 is a high-capacity urate transporter and its genetic impairment increases serum uric acid levels in humans. Nucleosides Nucleotides Nucleic Acids 2011, 30:1091-1097.
80. Bell D.R., Gerlach J.H., Kartner N., Buick R.N., Ling V. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J. Clin. Oncol. 1985, 3:311-315.
81. Mignogna C., Staibano S., Altieri V., De Rosa G., Pannone G., Santoro A., Zamparese R., D'Armiento M., Rocchetti R., Mezza E., Nasti M., Strazzullo V., Montanaro V., Mascolo M., Bufo P. Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis. BMC Cancer 2006, 6.
82. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res. 1986, 46:6387-6392.
83. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J. Control. Release 2012, 164:138-144.
84. Lammers T., Hennink W.E., Storm G. Tumour-targeted nanomedicines: principles and practice. Br. J. Cancer 2008, 99:392-397.
85. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 2010, 7:653.
86. Ambudkar S.V., Kim I.W., Sauna Z.E. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur. J. Pharm. Sci. 2006, 27:392-400.
87. Batrakova E.V., Li S., Elmquist W.F., Miller D.W., Alakhov V.Y., Kabanov A.V. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion. Br. J. Cancer 2001, 85:1987-1997.
88. Kabanov A.V., Batrakova E.V., Alakhov V.Y. Pluronic® block copolymers for overcoming drug resistance in cancer. Adv. Drug Deliv. Rev. 2002, 54:759-779.
89. Uversky V.N., Kabanov A.V., Lyubchenko Y.L. Nanotools for megaproblems: probing protein misfolding diseases using nanomedicine modus operandi. J. Proteome Res. 2006, 5:2505-2522.
90. Kabanov A.V., Gendelman H.E. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog. Polym. Sci. 2007, 32:1054-1082.
91. Batrakova E.V., Kabanov A.V. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J. Control. Release 2008, 130:98-106.
92. Sahay G., Alakhova D.Y., Kabanov A.V. Endocytosis of nanomedicines. J. Control. Release 2010, 145:182-195.
93. Kabanov A., Bronich T. Eighth international nanomedicine and drug delivery symposium (NanoDDS'10). J. Control. Release 2011, 153. 1-1.
94. Chen Y., Zhang W., Gu J., Ren Q., Fan Z., Zhong W., Fang X., Sha X. Enhanced antitumor efficacy by methotrexate conjugated Pluronic mixed micelles against KBv multidrug resistant cancer. Int. J. Pharm. 2013, 452:421-433.
95. Kunjachan S., Blauz A., Mockel D., Theek B., Kiessling F., Etrych T., Ulbrich K., van Bloois L., Storm G., Bartosz G., Rychlik B.Å., Lammers T. Overcoming cellular multidrug resistance using classical nanomedicine formulations. Eur. J Pharm. Science 2012, 45:421-428.
96. Kievit F.M., Wang F.Y., Fang C., Mok H., Wang K., Silber J.R., Ellenbogen R.G., Zhang M. Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. J. Control. Release 2011, 152:76-83.
97. Wang J., Goh B., Lu W., Zhang Q., Chang A., Liu X.Y., Tan T.M.C., Lee H. In vitro cytotoxicity of stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol. Pharm. Bull. 2005, 28:822-828.
98. Patel N.R., Rathi A., Mongayt D., Torchilin V.P. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int. J. Pharm. 2011, 416:296-299.
99. Wong H.L., Bendayan R., Rauth A.M., Wu X.Y. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J. Control. Release 2006, 116:275-284.
100. Xiong X.B., Lavasanifar A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano 2011, 5:5202-5213.
101. Saad M., Garbuzenko O.B., Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond.) 2008, 3:761-776.
102. Soma C.E., Dubernet C., Bentolila D., Benita S., Couvreur P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 2008, 21:1-7.
103. Wang J.C., Liu X.Y., Lu W.L., Chang A., Zhang Q., Goh B.C., Lee H.S. Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats. Eur. J. Pharm. Biopharm. 2006, 62:44-51.
104. Wu J., Lu Y., Lee A., Pan X., Yang X., Zhao X., Lee R.J. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J. Pharm. Pharm. Sci. 2007, 10:350-357.
105. Du J., Lu W.L., Ying X., Liu Y., Du P., Tian W., Men Y., Guo J., Zhang Y., Li R.J., Zhou J., Lou J.N., Wang J.C., Zhang X., Zhang Q. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol. Pharm. 2009, 6:905-917.
106. Patil Y., Sadhukha T., Ma L., Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control. Release 2009, 136:21-29.
107. Song X.R., Cai Z., Zheng Y., He G., Cui F.Y., Gong D.Q., Hou S.X., Xiong S.J., Lei X.J., Wei Y.Q. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur. J. Pharm. Sci. 2009, 37:300-305.
108. Song X.R., Zheng Y., He G., Yang L., Luo Y.F., He Z.Y., Li S.Z., Li J.M., Yu S., Luo X., Hou S.X., Wei Y.Q. Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma. J. Pharm. Sci. 2011, 99:4874-4879.
109. Nieto Montesinos R., Beduneau A., Pellequer Y., Lamprecht A. Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes. J. Control. Release 2012, 161:50-61.